deltatrials
Completed PHASE2 INTERVENTIONAL NCT00010179

Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer

Randomized Phase II Study Of NX 211 Given By Two Different Intravenous Schedules In Advanced And/Or Recurrent Epithelial Ovarian Cancer

Sponsor: NCIC Clinical Trials Group

Interventions lurtotecan liposome
Updated 8 times since 2017 Last updated: Apr 2, 2020 Started: Oct 31, 2000 Primary completion: Oct 22, 2002 Completion: Sep 22, 2008
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Fallopian Tube Cancer and Ovarian Cancer and is currently completed. NCIC Clinical Trials Group leads this study, which shows 8 recorded versions since 2000 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Apr 2020 · 22 months · monthly snapshotCompleted~Apr 2020 – ~May 2020 · 30 days · monthly snapshotCompleted~May 2020 – ~Jan 2021 · 8 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 11 months · monthly snapshotCompleted

Change History

8 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. May 2020 — Jan 2021 [monthly]

    Completed PHASE2

Show 3 earlier versions
  1. Apr 2020 — May 2020 [monthly]

    Completed PHASE2

  2. Jun 2018 — Apr 2020 [monthly]

    Completed PHASE2

  3. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Oct 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NCIC Clinical Trials Group
Data source: Canadian Cancer Trials Group

For direct contact, visit the study record on ClinicalTrials.gov .